In theory, there are no changes to the conformity assessment
of device-drug combinations with the MDR, unless the device
itself requires the additional scrutiny procedure. The additional
requirements for UDI, PMS, clinical evaluation etc. introduced
by the MDR will also apply to these devices. However, the words
‘liable to act’ have been removed from Rule 14, so there may be
more devices requiring medicinal consultation.
